

United States Senate

COMMITTEE ON FINANCE

WASHINGTON, DC 20510-6200

December 11, 2025

Dr. Albert Bourla
Chief Executive Officer
Pfizer, Inc.
66 Hudson Blvd. East
New York, NY 10001

Dear Dr. Bourla:

On July 4, 2025, President Trump signed the Republican reconciliation bill (H.R. 1) into law. That bill included nearly \$900 billion in cuts to the Medicaid program, which will create disastrous consequences for state budgets, and, in turn, access to health care services for Americans all across the country. States have few options when it comes to filling the hole left by massive federal cuts – all of which lead to less access for patients. States can either cut provider rates, cut services, or cut eligibility for Medicaid – each of these options will make Americans sicker, force hospitals to close and cut services, and increase health care costs for all.

The deep Medicaid cuts in H.R. 1 have put states in the impossible position of trying to figure out how to keep our Medicaid programs afloat and ensure continued patient access across the health care system writ large. With that in mind, we write today to seek more information from Pfizer about which drugs are subject to the Medicaid components of your agreement with the Trump Administration and whether the prices you will make available on these drugs are actually lower than the net pricing states currently receive on the same products in Medicaid.

On September 30, 2025, you held a press conference with President Trump announcing that Pfizer would offer “most-favored nation” pricing on certain prescription drugs in Medicaid. It is clear that Pfizer stands to gain a lot from this agreement, including relief from tariffs and potential priority review of new drug applications at the Food and Drug Administration (FDA). The Trump Administration is also pressuring other countries, such as the U.K., to pay higher prices for drugs, which will further increase revenues for industry, even though it is unclear whether industry will be expected to proportionally lower pricing in the U.S.

It is difficult to discern, however, what patients in Medicaid and taxpayers stand to gain from your agreement with the Trump Administration. On November 6, 2025, CMS announced the Generating Cost Reductions for U.S. Medicaid Model (GENEROUS) model and released a corresponding request for applications from manufacturers. The GENEROUS model is a voluntary demonstration program under which CMS will negotiate supplemental rebates and coverage terms on prescription drugs with participating manufacturers. The Trump Administration claims that these rebates will bring Medicaid drug costs closer to international

pricing on covered outpatient drugs for states that choose to participate in the model. Presumably, manufacturers like Pfizer that have announced agreements with the Trump Administration will be able to effectuate the Medicaid components of those agreements through the GENEROUS model.

States won't benefit if GENEROUS model prices are essentially the same as current Medicaid net prices or higher. Medicaid already pays the lowest drug prices in the U.S., often in line with the prices paid in other wealthy countries. For example, a 2021 analysis by the Congressional Budget Office (CBO) found that the average net price of top-selling brand drugs in Medicaid was \$118, relative to an average price of \$343 in Medicare Part D.¹ Critical details about the GENEROUS model also remain unclear, including whether manufacturers can seek exemptions for the drugs where this model could potentially have the greatest impact. Furthermore, the RFA explicitly states that terms under CMS agreements with manufacturers can differ from the terms CMS just publicly released about the model. Thus, it is difficult to draw any firm conclusions about what pricing manufacturers will have to offer states under the model and on which drugs.

Attached to this letter, you will find a table listing brand drugs currently marketed by Pfizer and a list of Pfizer subsidiary and affiliate companies. We ask that Pfizer promptly respond by populating those tables and providing the following information:

1. Does Pfizer plan to effectuate the Medicaid components of its drug pricing agreement with the Trump Administration through the GENEROUS model? If not, please explain how Pfizer will effectuate its Medicaid drug pricing agreement with the Trump Administration.
2. During which calendar years does Pfizer plan to either participate in the GENEROUS model or otherwise offer agreed upon pricing to state Medicaid programs pursuant to your agreement with the Trump Administration?
3. Please populate Table 1 by:
 - a. Identifying which drugs in your current book of business are subject to the Medicaid part of your agreement with the Trump Administration and/or will be included in the GENEROUS model;
 - b. Providing the second lowest country specific average net price on each drug identified above over the last 12 months from the following countries: the United Kingdom, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland²;

¹ CBO. A Comparison of Brand-Name Drug Prices Across Selected Federal Programs. February 2021. Available at: <https://www.cbo.gov/publication/57007>


² While we recognize that this price might not be the same as model pricing under the GENEROUS model, this pricing methodology appears to generally reflect what the Trump Administration in its request for applications from manufacturers is purporting to deliver states. Pricing information along these lines will presumably be released fairly broadly to states. Therefore, we think it is reasonable to ask manufacturers to release this information. It will be helpful for states to have this information in order to compare this price point to the pricing ultimately offered under the GENEROUS model and/or pursuant to your agreement with the Trump Administration.

- c. Providing the net price available to state Medicaid programs under your agreement with the Trump Administration and/or the GENEROUS model for each such drug identified above³; and
 - d. Confirming whether the price listed above is lower than the lowest net price Pfizer currently offers to any state Medicaid program for such drug (including both statutorily required rebates under the Medicaid Drug Rebate Program and any supplemental rebates).
- 4. Please populate Table 2 by:
 - a. Listing all drugs marketed in the United States under labels of Pfizer subsidiary or affiliate companies;
 - b. Identifying which drugs among those listed above are subject to the Medicaid part of your agreement with the Trump Administration and/or will be included in the GENEROUS model;
 - c. Providing the second lowest country specific average net price on each drug identified above over the last 12 months from the following countries: the United Kingdom, France, Germany, Italy, Canada, Japan, Denmark, and Switzerland;
 - d. Providing the net price available to state Medicaid programs under your agreement with the Trump Administration and/or the GENEROUS model for each such drug identified above; and
 - e. Confirming whether the price listed above is lower than the lowest net price Pfizer currently offers to any state Medicaid program for such drug (including both statutorily required rebates under the Medicaid Drug Rebate Program and any supplemental rebates).
- 5. If Pfizer is effectuating the Medicaid components of your agreement with the Trump Administration through a method other than the GENEROUS model:
 - a. Please explain how state Medicaid programs would receive any additional discounts or rebates on the relevant drugs.
 - b. In order to access any additional discounts on Pfizer drugs under the agreement, would state Medicaid programs need to agree to any conditions related to coverage, formulary placement, or utilization management for such drugs? If yes, would states have to opt into the agreement with respect to the entire bundle of drugs subject to the arrangement? Or could states make separate decisions with respect to each individual drug?
 - c. How would any additional discounts or rebates relate to the statutorily required rebates under the Medicaid Drug Rebate Program or supplemental rebates obtained by state Medicaid programs?


States need timely access to this information in order to make urgent state budgetary decisions due to the loss of Medicaid funding, including during special sessions and in preparation of budgets for the upcoming state fiscal year, and prioritize preserving patient access to health care. Therefore, we ask that you provide this information no later than January 30, 2026.

³ As noted above, pricing information under the GENEROUS model and/or pursuant to manufacturer agreements with the Trump Administration will presumably be released fairly broadly to states. Therefore, we think it is reasonable to ask manufacturers to release this information.


Sincerely,



Ron Wyden
United States Senator
Ranking Member, Committee
on Finance



Jeffrey A. Merkley
United States Senator




Richard J. Durbin
United States Senator



John Hickenlooper
United States Senator




Christopher S. Murphy
United States Senator



Amy Klobuchar
United States Senator



Elizabeth Warren
United States Senator



Michael F. Bennet
United States Senator

Table 1: Drugs Marketed Under Pfizer Label

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
ABRILADA	0025-0325-01					
ABRILADA	0025-0325-02					
ABRILADA	0025-0328-02					
ABRILADA	0025-0333-02					
ABRILADA	0069-0325-01					
ABRILADA	0069-0325-02					
ABRILADA	0069-0328-02					
ABRILADA	0069-0333-02					
Abrysvo	0069-2465-01					
Abrysvo	0069-2465-10					
Abrysvo	0069-0344-01					
Abrysvo	0069-0344-05					
Abrysvo	0069-0344-10					
Accupril	0071-0527-23					
Accupril	0071-0530-23					
Accupril	0071-0532-23					
Accupril	0071-0535-23					
ACCURETIC	0071-3112-23					
ACCURETIC	0071-5212-23					
Aldactone	0025-1001-31					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Aldactone	0025-1031-31					
Aldactone	0025-1041-31					
ALTACE	61570-120-01					
ARTHROTEC	0025-1411-60					
ARTHROTEC	0025-1411-90					
ARTHROTEC	0025-1421-60					
Azulfidine	0013-0101-10					
Azulfidine	0013-0101-30					
Azulfidine	0013-0102-50					
Azulfidine	0013-0102-60					
Besponsa	0008-0100-01					
BICILLIN C-R 900/300	60793-602-10					
BICILLIN CR	60793-600-10					
BICILLIN CR	60793-601-10					
BICILLIN L-A	60793-700-10					
BICILLIN L-A	60793-701-10					
BICILLIN L-A	60793-702-10					
BOSULIF	0069-0135-01					
BOSULIF	0069-0136-01					
BOSULIF	0069-0193-01					
BOSULIF	0069-0504-30					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
BOSULIF	0069-1014-15					
Caduet	0069-2260-30					
Caduet	0069-6180-30					
Caduet	0069-6323-30					
Caduet	0069-6565-30					
Caduet	0069-6747-30					
Caduet	0069-7232-30					
Caduet	0069-7476-30					
Caduet	0069-7654-30					
Caduet	0069-7810-30					
Celontin	0071-0525-24					
CEREBYX	0069-5471-02					
CEREBYX	0069-5474-02					
CEREBYX	0069-6001-21					
CEREBYX	0069-6001-25					
CHANTIX	0069-0468-56					
CHANTIX	0069-0469-56					
Cibinqo	0069-0235-30					
Cibinqo	0069-0335-30					
Cibinqo	0069-0435-30					
Comirnaty	0069-2501-10					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Comirnaty	0069-2528-10					
Comirnaty	0069-2432-10					
Cutaquig	0069-1802-02					
Cutaquig	0069-1960-02					
Cutaquig	0069-1965-02					
Cutaquig	0069-1061-02					
Cutaquig	0069-1476-02					
Cutaquig	0069-1509-02					
Cyklokapron	0013-1114-15					
Cyklokapron	0013-1114-21					
Cytomel	60793-115-01					
Cytomel	60793-116-01					
Cytomel	60793-117-01					
Cytotec	0025-1451-34					
Cytotec	0025-1451-60					
Cytotec	0025-1461-31					
Cytotec	0025-1461-60					
Daurismo	0069-0298-60					
Daurismo	0069-1531-30					
Daypro	0025-1381-31					
Dilantin	0071-0369-24					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Dilantin	0071- 0369-32					
Dilantin	0071- 0369-40					
Dilantin	0071- 3740-66					
Dilantin Infatabs	0071- 0007-24					
Dilantin Infatabs	0071- 0007-40					
Doxorubicin Hydrochloride	0069- 0343-02					
Doxorubicin Hydrochloride	0069- 3358-25					
Doxorubicin Hydrochloride	0069- 4205-05					
Doxorubicin Hydrochloride	0069- 0277-02					
Doxorubicin Hydrochloride	0069- 3030-20					
Doxorubicin Hydrochloride	0069- 3031-20					
Doxorubicin Hydrochloride	0069- 3032-20					
Doxorubicin Hydrochloride	0069- 3034-20					
Doxorubicin Hydrochloride	0069- 4004-05					
Doxorubicin Hydrochloride	0069- 4015-10					
Doxorubicin Hydrochloride	0069- 1542-20					
Doxorubicin Hydrochloride	0069- 4026-25					
Doxorubicin Hydrochloride	0069- 4037-01					
Doxorubicin Hydrochloride	0069- 4031-12					
Doxorubicin Hydrochloride	0069- 5629-05					
Doxorubicin Hydrochloride	0069- 0255-10					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Doxorubicin Hydrochloride	0069-1442-04					
Doxorubicin Hydrochloride	0069-0358-20					
Duavee	0008-1123-12					
Effexor	0008-0833-21					
Effexor	0008-0833-22					
Effexor	0008-0836-21					
ELELYSO	0069-0106-01					
Elrex fio	0069-2522-02					
Elrex fio	0069-4494-02					
Estring	0013-1042-01					
Eucrisa	55724-211-11					
Eucrisa	55724-211-21					
Eucrisa	55724-211-23					
Eucrisa	55724-211-42					
Flagyl	0025-1942-34					
Fragmin	0069-0195-02					
Fragmin	0069-0196-02					
Fragmin	0069-0206-02					
Fragmin	0069-0217-02					
Fragmin	0069-0220-02					
Fragmin	0069-0223-02					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Fragmin	0069-0228-02					
Fragmin	0069-0232-01					
Fragmin	0069-0253-10					
GENOTROPIN	0013-2626-81					
GENOTROPIN	0013-2646-81					
GENOTROPIN	0013-2649-02					
GENOTROPIN	0013-2650-02					
GENOTROPIN	0013-2651-02					
GENOTROPIN	0013-2652-02					
GENOTROPIN	0013-2653-02					
GENOTROPIN	0013-2654-02					
GENOTROPIN	0013-2655-02					
GENOTROPIN	0013-2656-02					
GENOTROPIN	0013-2657-02					
GENOTROPIN	0013-2658-02					
Heparin Sodium	0069-0043-01					
HYMPAVZI	0069-2151-01					
Ibrance	0069-0187-21					
Ibrance	0069-0188-21					
Ibrance	0069-0189-21					
Ibrance	0069-0284-03					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Ibrance	0069-0486-03					
Ibrance	0069-0688-03					
Idamycin PFS	0013-2576-05					
Idamycin PFS	0013-2576-91					
Idamycin PFS	0013-2586-10					
Idamycin PFS	0013-2586-91					
Idamycin PFS	0013-2596-20					
Idamycin PFS	0013-2596-91					
INFLECTRA	0069-0809-01					
INLYTA	0069-0145-01					
INLYTA	0069-0151-11					
LEVOXYL	60793-850-01					
LEVOXYL	60793-850-10					
LEVOXYL	60793-851-01					
LEVOXYL	60793-851-10					
LEVOXYL	60793-852-01					
LEVOXYL	60793-852-10					
LEVOXYL	60793-853-01					
LEVOXYL	60793-853-10					
LEVOXYL	60793-854-01					
LEVOXYL	60793-854-10					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
LEVOXYL	60793-855-01					
LEVOXYL	60793-855-10					
LEVOXYL	60793-856-01					
LEVOXYL	60793-856-10					
LEVOXYL	60793-857-01					
LEVOXYL	60793-857-10					
LEVOXYL	60793-858-01					
LEVOXYL	60793-858-10					
LEVOXYL	60793-859-01					
LEVOXYL	60793-859-10					
LEVOXYL	60793-860-01					
LEVOXYL	60793-860-10					
Lipitor	0071-0157-23					
Litfulo	0069-0334-28					
Lomotil	0025-0061-31					
Lopid	0071-0737-20					
Lopid	0071-0737-30					
Lorbrena	0069-0227-01					
Lorbrena	0069-0231-01					
Lorbrena	0069-0227-03					
Lyrica	0071-1012-68					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Lyrica	0071-1013-41					
Lyrica	0071-1013-68					
Lyrica	0071-1014-41					
Lyrica	0071-1014-68					
Lyrica	0071-1015-41					
Lyrica	0071-1015-68					
Lyrica	0071-1016-41					
Lyrica	0071-1016-68					
Lyrica	0071-1017-68					
Lyrica	0071-1018-68					
Lyrica	0071-1019-68					
Lyrica	0071-1020-01					
Lyrica CR	0071-1026-01					
Lyrica CR	0071-1027-01					
MENEST	61570-072-01					
MENEST	61570-073-01					
MENEST	61570-074-01					
MENEST	61570-075-50					
Mycobutin	0013-5301-17					
Mylotarg	0008-4510-01					
Nardil	0071-0350-60					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Neurontin	0071-0401-24					
Neurontin	0071-0513-24					
Neurontin	0071-0803-24					
Neurontin	0071-0805-24					
Neurontin	0071-0806-24					
Neurontin	0071-2012-47					
Ngenla	0069-0505-02					
Ngenla	0069-0520-02					
Nitrostat	0071-0417-24					
Nivestym	0069-0291-01					
Nivestym	0069-0291-10					
Nivestym	0069-0292-01					
Nivestym	0069-0292-10					
Nivestym	0069-0293-10					
Nivestym	0069-0294-10					
Norpace	0025-2752-31					
Norpace	0025-2762-31					
Norpace CR	0025-2732-31					
Norpace CR	0025-2742-31					
North American Coral Snake Antivenin (Equine)	0008-0423-03					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Norvasc	0069-1520-68					
Norvasc	0069-1530-68					
Norvasc	0069-1530-72					
Norvasc	0069-1540-68					
NURTEC ODT	72618-3000-2					
NURTEC ODT	72618-3001-2					
NYVEPRIA	0069-0324-01					
Octagam Immune Globulin (Human)	0069-6002-02					
Octagam Immune Globulin (Human)	0069-6111-02					
Octagam Immune Globulin (Human)	0069-6237-02					
Octagam Immune Globulin (Human)	0069-6339-02					
Octagam Immune Globulin (Human)	0069-6550-02					
Octagam Immune Globulin (Human)	0069-8400-02					
Octagam Immune Globulin (Human)	0069-8425-02					
Octagam Immune Globulin (Human)	0069-8451-02					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Octagam Immune Globulin (Human)	0069- 8476-02					
OXBRYTA	72786- 101-01					
OXBRYTA	72786- 102-02					
OXBRYTA	72786- 102-03					
OXBRYTA	72786- 111-02					
OXBRYTA	72786- 111-03					
Panzyga	0069- 1011-02					
Panzyga	0069- 1109-02					
Panzyga	0069- 1224-02					
Panzyga	0069- 1312-02					
Panzyga	0069- 1415-02					
Panzyga	0069- 1558-02					
Paxlovid	0069- 5045-30					
Paxlovid	0069- 5434-20					
Paxlovid	0069- 5317-20					
Paxlovid	0069- 5321-30					
Paxlovid	0069- 0521-11					
PENBRAYA	0069- 0600-01					
PENBRAYA	0069- 0600-05					
PENBRAYA	0069- 0600-10					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Premarin	0046-1100-81					
Premarin	0046-1100-91					
Premarin	0046-1101-81					
Premarin	0046-1102-81					
Premarin	0046-1102-91					
Premarin	0046-1103-81					
Premarin	0046-1104-81					
Premarin	0046-1104-91					
Premarin	0046-0749-05					
Premarin	0046-0872-04					
Premarin	0046-0872-21					
Premarin	0046-1100-52					
Premarin	0046-1102-52					
Premphase	0046-2575-12					
Prempro	0046-1105-11					
Prempro	0046-1106-11					
Prempro	0046-1107-11					
Prempro	0046-1108-11					
Pristiq	0008-1210-30					
Pristiq	0008-1222-01					
Pristiq	0008-1222-14					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Pristiq	0008-1222-30					
Pristiq	0008-1222-50					
Pristiq	0008-1211-01					
Pristiq	0008-1211-14					
Pristiq	0008-1211-30					
Pristiq	0008-1211-50					
Procardia	0069-2650-41					
Procardia	0069-2650-66					
Procardia	0069-2650-72					
Procardia	0069-2660-41					
Procardia	0069-2660-66					
Procardia	0069-2660-72					
Procardia	0069-2670-66					
Propofol	0069-0209-10					
Propofol	0069-0234-20					
Propofol	0069-0248-10					
Protonix	0008-0923-51					
Protonix	0008-0923-55					
Protonix	0008-0923-60					
Protonix	0008-4001-10					
Protonix	0008-4001-25					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Protonix	0008-0841-81					
Protonix	0008-0843-81					
Protonix	0008-0844-02					
Rapamune	0008-1041-05					
Rapamune	0008-1042-05					
RETACRIT	0069-1305-10					
RETACRIT	0069-1306-10					
RETACRIT	0069-1307-10					
RETACRIT	0069-1308-10					
RETACRIT	0069-1309-04					
RETACRIT	0069-1311-10					
RETACRIT	0069-1318-10					
Revatio	0069-0336-21					
Revatio	0069-0338-01					
Revatio	0069-4190-68					
Ruxience	0069-0238-01					
Ruxience	0069-0249-01					
SILVADENE	61570-131-20					
SILVADENE	61570-131-25					
SILVADENE	61570-131-40					
SILVADENE	61570-131-50					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
SILVADENE	61570-131-55					
SILVADENE	61570-131-85					
SILVADENE	61570-131-98					
SUTENT	0069-0550-38					
SUTENT	0069-0770-38					
SUTENT	0069-0830-38					
SUTENT	0069-0980-38					
Synarel	0025-0166-08					
Talzenna	0069-1751-30					
Talzenna	0069-0252-30					
Talzenna	0069-0296-30					
Talzenna	0069-0353-30					
Talzenna	0069-0454-30					
Talzenna	0069-0546-30					
Talzenna	0069-0655-30					
Talzenna	0069-0757-30					
Talzenna	0069-1031-30					
Talzenna	0069-1195-30					
Talzenna	0069-1235-30					
Talzenna	0069-1501-30					
THROMBIN-JMI	60793-217-20					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
THROMBIN-JMI	60793-217-21					
THROMBIN-JMI	60793-217-22					
THROMBIN-JMI	60793-705-05					
THROMBIN-JMI	60793-205-05					
THROMBIN-JMI	60793-215-05					
TicoVac	0069-0297-02					
TicoVac	0069-0297-10					
TicoVac	0069-0411-02					
TicoVac	0069-0411-10					
Tikosyn	0069-5800-60					
Tikosyn	0069-5800-61					
Tikosyn	0069-5810-60					
Tikosyn	0069-5810-61					
Tikosyn	0069-5820-60					
Tikosyn	0069-5820-61					
Torisel	0008-1179-01					
Toviaz	0069-0242-30					
Toviaz	0069-0244-30					
Trazimera	0069-0305-01					
Trazimera	0069-0308-01					
Trecator	0008-4117-01					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Tygacil	0008-4994-20					
Tygacil	0008-4990-20					
Velsipity	0069-0274-30					
Viagra	0069-4200-30					
Viagra	0069-4210-30					
Viagra	0069-4210-66					
Viagra	0069-4220-30					
Viagra	0069-4220-66					
Vistaril	0069-5410-66					
Vizimpro	0069-2299-30					
Vizimpro	0069-0197-30					
Vizimpro	0069-1198-30					
Vyndamax	0069-8730-30					
Vyndaqel	0069-1975-40					
Xalatan	0013-8303-04					
Xalkori	0069-0251-60					
Xalkori	0069-0507-60					
Xalkori	0069-1500-60					
Xalkori	0069-8140-20					
Xalkori	0069-8141-20					
XELJANZ	0069-0501-30					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
XELJANZ	0069-0502-30					
XELJANZ	0069-1001-01					
XELJANZ	0069-1002-01					
XELJANZ	0069-1029-02					
Zarontin	0071-0237-24					
Zarontin	0071-2418-19					
ZAVZPRET	0069-3500-02					
Zirabev	0069-0315-01					
Zirabev	0069-0342-01					
ZITHROMAX	0069-3051-75					
Zithromax	0069-3060-75					
Zithromax	0069-3070-30					
Zithromax	0069-3070-75					
Zithromax	0069-3110-19					
Zithromax	0069-3120-19					
Zithromax	0069-3130-19					
Zithromax	0069-3140-19					
Zithromax	0069-3150-83					
Zithromax	0069-0400-10					
Zithromax	0069-4061-01					
Zithromax	0069-4061-89					

Drug Name	NDC Package Code	Indication(s)	In GENEROUS/ Agreement? (Y/N)	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Zithromax	0069- 9500-01					
Zosyn	0206- 8860-02					
Zosyn	0206- 8861-02					
Zosyn	0206- 8862-02					

Table 2: Drugs Marketed Under Pfizer Subsidiary or Affiliate Labels

Company	List of Brand Drugs Marketed in the U.S. and Indications	List of Drugs in GENEROUS/ Agreement	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Agouron Pharmaceuticals					
Alpharma Pharmaceuticals					
Amplix Pharmaceuticals					
Anacor Pharmaceutical					
Angiosyn					
Arena Pharmaceuticals					
Arixa Pharmaceuticals					
Array Biopharma					
Bamboo Therapeutics					
Baxter International – Marketed Vaccines					
Bind Therapeutics					
Biohaven Pharmaceutical					
Bioren					
Biorexis					
C.P. Pharmaceuticals International					
Catapult Genetics					
Coley Pharmaceutical Group					
Covx					
Encysive Pharmaceuticals					
Esperion					
Excaliard Pharmaceuticals					
Foldrx Pharmaceuticals					
Global Blood Therapeutics					
Hospira					
Icagen					

Company	List of Brand Drugs Marketed in the U.S. and Indications	List of Drugs in GENEROUS/ Agreement	Second Lowest Country Specific Net Price	Medicaid Net Price Under Agreement/ GENEROUS	Lower than Current Net Price in Medicaid? (Y/N)
Idun Pharmaceuticals					
Ignite Immunotherapy					
Innopharma					
King Pharmaceuticals					
Medivation					
Nextwave Pharmaceuticals					
Pharmacia					
Powdermed					
Redvax					
Resapp Health					
Reviral					
Rinat Neuroscience					
Seagen					
Serenex					
Therachon					
Trillium Therapeutics					
Warner-Lambert					
Wyeth Biopharma					